Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 351

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 1B
Chunk 351
---
 for evaluation by the chief operating
decision maker in deciding how to allocate resources in assessing performance. The Company operates as a single reporting segment, focusing
on the development of a novel and patented systemically administered anti-cancer and anti-viral immunotherapy. The Company’s chief
operating decision maker (“CODM”) is the chief executive officer.

The
accounting policies of the segment are the same as those described in the summary of significant accounting policies. The CODM assesses
performance for the segment based on operating expenses as reported in the accompanying consolidated statement of operations. The Company
expects to continue to incur significant expenses and operating losses for the foreseeable future as it advances the development of its
product candidates through pre-clinical and clinical trials. In addition, the measure of segment assets is reported on the accompanying
consolidated balance sheet as total assets.

    F-16

As
such, the CODM uses cash forecast models in deciding how to invest into the segment. Such cash forecast models are reviewed to assess
the entity-wide operating results and performance. Net loss is used to monitor budget versus actual results. Monitoring budgeted versus
actual results is used in assessing performance of the segment.

The
following table presents reportable segment loss, including significant expenses regularly provided to the CODM, attributable to the
Company’s reportable segment for the years ended December 31, 2024 and 2023:

SCHEDULE
OF REPORTABLE SEGMENT LOSS 

    2024  
    2023 

    Year ended December 31, 

    2024  
    2023 
  
    Research and development: 

    External research and development 
    $4,355,449  
    $4,683,828 
  
    Internal personnel costs 
     2,895,648  
     2,937,879 
  
    Total research and development 
     7,251,097  
     7,621,707 
  
    General and administrative 
     8,114,654  
     8,756,767 
  
    Other income, net 
     (343,724) 
     (955,003)
  
    Net loss 
    $15,022,027  
    $15,423,471 

NOTE
10: SUBSEQUENT EVENTS

The
Company evaluated subsequent events from December 31, 2024, the date of these consolidated financial statements, through March